Protara Therapeutics Completes First Cohort Of Phase 2 STARBORN-1 Trial For TARA-002 In Pediatric Lymphatic Malformations; Enrollment Ongoing In Additional Cohorts With Initial Results Expected In 1H 2025
Portfolio Pulse from Benzinga Newsdesk
Protara Therapeutics has completed the first cohort of its Phase 2 STARBORN-1 trial for TARA-002, targeting pediatric lymphatic malformations. Enrollment for additional cohorts is ongoing, with initial results anticipated in the first half of 2025.
September 09, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protara Therapeutics has completed the first cohort of its Phase 2 trial for TARA-002, with ongoing enrollment and results expected in 1H 2025. This progress in clinical trials could positively impact the company's stock.
The completion of the first cohort in a Phase 2 trial is a significant milestone for Protara Therapeutics, indicating progress in their clinical development. This can boost investor confidence and potentially lead to a positive short-term impact on the stock price as the market anticipates further developments and results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100